The Passive Micro-Cap Footprint: A $1.5 Billion Fund, 1,360 Names and a 58% Year
For all the attention the micro-cap tier has drawn this year, the amount of indexed money formally tracking it remains modest. The iShares Micro-Cap ETF, the largest US fund built on the Russell Microcap Index, reported net assets of $1,506,653,387 as of August 10, according to BlackRock's fund page — a figure smaller than the market capitalization of many individual mid-cap companies.
That pool is spread thin. The fund held 1,360 positions as of the same date, meaning the average holding accounts for roughly one-tenth of one percent of assets. The structure explains a recurring feature of micro-cap trading: index-driven demand arrives in very small per-name increments, and the price impact of any single flow depends far more on a company's float than on the size of the flow itself.
The returns attached to that footprint have been outsized. BlackRock reported a year-to-date total return of 25.33% and a one-year return of 58.33% for the fund as of August 10. For context, the Russell 2000 had gained about 20% in 2026 as of mid-July, its strongest showing since 2003, according to reporting published by Yahoo Finance on July 16 — a spread that puts the smallest tier ahead of an already-strong small-cap benchmark.
Valuation data on the same fund page complicates the simple story that micro caps have run to excess. BlackRock listed a price-to-earnings ratio of 13.74 and a price-to-book ratio of 1.78 for the portfolio. Those multiples reflect only the profitable subset of constituents under standard index methodology, and a substantial share of the micro-cap universe carries negative trailing earnings, so headline multiples understate how much of the tier is valued on something other than current profits.
Sector composition is where the fund departs most sharply from broad market benchmarks. Health care accounted for 26.96% of holdings and financials 24.72%, per BlackRock's disclosure, with industrials at 12.69%, information technology at 11.44% and consumer discretionary at 7.50%. More than half the portfolio, in other words, sits in clinical-stage biotech and small community banks — two groups whose fortunes turn on trial data and the rate curve rather than on the AI capital-spending cycle driving large-cap indexes.
Volatility is priced accordingly. The fund's three-year standard deviation was 22.21% and its expense ratio 0.60%, both well above what investors pay or endure for large-cap index exposure. The higher fee reflects the cost of maintaining positions in more than a thousand thinly traded securities, where rebalancing itself can move prices.
None of this speaks to what comes next, and the fund's own disclosures emphasize that micro-cap securities carry greater liquidity and volatility risk than larger companies. What the data does establish is scale: a rally that has produced a 58% one-year gain in the indexed micro-cap complex has been driven by a relatively small base of dedicated passive capital, which means active buyers, retail flow and issuer supply are doing most of the work in setting prices at this end of the market.
That distinction matters for anyone reading micro-cap strength as evidence of institutional conviction. The indexed money is present, but at $1.5 billion across 1,360 names it is not the marginal price-setter it is in larger capitalization bands.
